Sarepta Therapeutics Inc SRPT shares are trading higher by $5.75, or 14 percent, at $46.83 in Wednesday's session.
The catalyst for the rally is the announcement of positive results in its study for the treatment of Duchenne Muscular Dystrophy.
See Also: Sarepta Marks A 'Very Important Day' For The DMD Community
After a higher open, Sarepta continued in the direction before peaking at $46.99. That was followed by an orderly decline to $44.74, which was far above the top of Tuesday's session ($41.50) and embarked on another rally.
The stock has come all the way back to make a new high for the session at $47.20 as of 1:23 p.m. EST. That marks the highest level for the stock since October 25, 2016, when it peaked at $48.58.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.